GlassScriptPhysician profile
Jennifer C Cheng
NPI 1487811386
$1,542.09
in general payments reported to CMS, 2019-2025
21 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $122 · 2021: $307 · 2022: $12.48 · 2023: $345 · 2024: $336 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.76 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $200.08 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $170.21 | 2019-2025 | Bexsero, Rotarix, Shingrix |
| Medtronic, INC. | $158.62 | 2023-2025 | Intellis Adaptivestim, Percept PC Brainsense |
| Novo Nordisk INC | $149.73 | 2019-2023 | Wegovy, Saxenda, Ozempic |
| Insightec,INC | $140.56 | 2021 | |
| Abbott Laboratories | $122.80 | 2023-2024 | Freestyle Libre 3 |
| Abbvie INC. | $107.44 | 2021-2023 | Ubrelvy, Viberzi, Linzess |
| Pfizer INC. | $107.38 | 2020-2025 | |
| Microtransponder, INC. | $65.57 | 2024 | |
| Amgen INC. | $64.15 | 2021-2025 | Evenity, Prolia |
| Currax Pharmaceuticals LLC | $58.64 | 2021-2024 | Nexletol, Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.08 | 2023-2024 | Trulance, Xifaxan |
| Janssen Pharmaceuticals, INC | $28.57 | 2021-2023 | Xarelto |
| Allergan, INC. | $27.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.67 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $18.95 | 2024 | Omnipod |
| Lilly USA, LLC | $16.77 | 2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.25 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.01 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.54 | 2021 | |
| Sumitomo Pharma America, INC. | $10.00 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.